BBIBP-CorV
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05069129 | Oct 2021 → Dec 2023 | COVID-19 | National Vaccine and Serum Institute, China | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07408297 | May 2022 → Jun 2024 | COVID-19 | Victoria Biomedical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT05409300 | Apr 2022 → Aug 2023 | COVID-19 | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2 | NCT04998240 | Dec 2021 → Sep 2022 | COVID-19 | International Vaccine Institute | Unknown | Mixed |
| Phase 31 trial | ||||||
| Phase 3 | NCT04984408 | Oct 2021 → Sep 2024 | COVID-19 | International Vaccine Institute | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05480436 | Aug 2022 → Jan 2023 | COVID-19, hemolytic anemia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05453487 | Jul → Oct 2022 | COVID-19, rabies | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04988048 Comparator | Aug → Sep 2021 | COVID-19 | Ministry of Public Health, Argentina | Unknown | No outcome recorded |
| Phase 2 | NCT04983537 Comparator | Jul → Sep 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Unknown | No outcome recorded |
| Phase 2 | NCT04962906 Comparator | Jul → Aug 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | China National Biotec Group Company Limited | Results 真实世界，新冠疫苗效力到底如何？ cnbg.com.cn ↗
研究表明，全程接种有较高的保护效果，全程接种组疫苗预防住院、急诊入院和死亡的有效性分别为79.8%、92.2%和97.1%。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | China National Biotec Group Company Limited | 真实世界，新冠疫苗效力到底如何？ cnbg.com.cn ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBIBP-CorV | “Three groups of healthy adults over 18 years of age (600 participants per group) who have administered two doses of BBIBP-CorV 4-6-month, 7-9-month and >9-month earlier,...” PMID 35760812 ↗ Jun 20229“This study will attempt to determine whether administration of a heterologous regimen combining a first dose of Gam-COVID-Vac with a second dose of ChAdOx1 nCoV-19 or...” NCT04962906 ↗ “the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28” NCT05480436 ↗ “Sinopharm's BBIBP-CorV and Sinovac's CoronaVac are inactivated whole-virus COVID-19 vaccines.” NCT07408297 ↗ “BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China.” NCT04988048 ↗ “an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV)” NCT05453487 ↗ |
| Known as | Inactivated SARS-CoV-2 vaccine (Vero cell) | “The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by” NCT04998240 ↗ |
| Known as | SINOPHARM (BBIBP-CorV) | “an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV)” NCT05453487 ↗1“SINOPHARM (BBIBP-CorV)” NCT04988048 ↗ |
| Known as | Sinopharm / CNBG Vaccine | “Sinopharm / CNBG Vaccine (BBIBP-CorV)” NCT04998240 ↗ |
| Modality | Vaccine | “The BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell)” NCT04984408 ↗ |
| Route | Intramuscular | “Mode of Administration: Intramuscular” NCT04984408 ↗ |